Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II multicentre open label trial evaluating the efficacy and safety of the liopsomal doxorubicin (Myocet) and docetaxel (Taxotere) combination as first-line treatment of patients with metastatic HER2/neu negative breast cancer.

Next Previous
Trial Profile

Phase II multicentre open label trial evaluating the efficacy and safety of the liopsomal doxorubicin (Myocet) and docetaxel (Taxotere) combination as first-line treatment of patients with metastatic HER2/neu negative breast cancer.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 20 Dec 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 18 Nov 2009 Actual number of patients (70) added and trial sponsor changed from Zeneus Pharma to Cephalon as reported by ClinicalTrials.gov
  • 17 Nov 2009 Actual end date (1 Nov 2009) added as reported by ClinicalTrials.gov
  • 17 Nov 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top